Log in
NASDAQ:GLSI

Greenwich LifeSciences Stock Forecast, Price & News

$3.51
-0.16 (-4.36 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.51
Now: $3.51
$3.92
50-Day Range N/A
52-Week Range
$3.48
Now: $3.51
$5.75
Volume7,256 shs
Average Volume14,534 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLSI
CUSIPN/A
CIKN/A
Phone832-819-3232
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$3.51
-0.16 (-4.36 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLSI News and Ratings via Email

Sign-up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Greenwich LifeSciences (NASDAQ:GLSI) Frequently Asked Questions

Who are some of Greenwich LifeSciences' key competitors?

Who are Greenwich LifeSciences' key executives?

Greenwich LifeSciences' management team includes the following people:
  • Ms. Snehal S. Patel, CEO, CFO & Director (Age 56)
  • Dr. Frank Joseph Daugherty, Chief Medical Officer & Director (Age 70)

When did Greenwich LifeSciences IPO?

(GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

What is Greenwich LifeSciences' stock symbol?

Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI."

When does Greenwich LifeSciences' quiet period expire?

Greenwich LifeSciences' quiet period expires on Wednesday, November 4th. Greenwich LifeSciences had issued 1,260,870 shares in its IPO on September 25th. The total size of the offering was $7,250,003 based on an initial share price of $5.75. During Greenwich LifeSciences' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Greenwich LifeSciences' stock price today?

One share of GLSI stock can currently be purchased for approximately $3.51.

What is Greenwich LifeSciences' official website?

The official website for Greenwich LifeSciences is www.greenwichlifesciences.com.

How can I contact Greenwich LifeSciences?

The company can be reached via phone at 832-819-3232 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.